Trials / Completed
CompletedNCT04752631
MRI-guided thrOmbolysis for Stroke bEyond Time Window by TNK
MRI-guided thrOmbolysis for Stroke bEyond Time Window by TNK (ROSE-TNK): a Prospective, Randomized, Blinded Assessment of Outcome and Open Label Multi-center Study
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 80 (actual)
- Sponsor
- General Hospital of Shenyang Military Region · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label multicentre trial, evaluating the utility of MRI-guided thrombolysis for stroke beyond time window by Tenecteplase (TNK-tPA). This exploratory study was to describe the feasibility and outcome of thrombolytic therapy with TNK-tPA in 4.5-24 hours after stroke guided by a mismatch between diffusion-weighted imaging and FLAIR in the region of ischemia.
Detailed description
In patients with acute stroke with an unknown time of onset, intravenous alteplase guided by a mismatch between diffusion-weighted imaging and FLAIR in the region of ischemia resulted in a significantly better functional outcome at 90 days. This trial will enroll acute ischemic stroke patients within 4.5 to 24 hours of onset. All the patients had an ischemic lesion that was visible on MRI diffusion-weighted imaging but no parenchymal hyperintensity on fluid-attenuated inversion recovery (FLAIR), which indicated that the stroke had a ischemic penumbra. Randomization will be 1:1 to TNK-tPA (experimental) or standard treatment (control), in compliance with guidelines for acute stroke. Clinical outcome was assessed by disability on the basis of the modified Rankin scale at 90 days follow-up, which will be performed by a blinded assessor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tenecteplase | The participants received TNK-tPA thrombolytic therapy |
Timeline
- Start date
- 2021-03-09
- Primary completion
- 2022-07-24
- Completion
- 2022-07-24
- First posted
- 2021-02-12
- Last updated
- 2022-08-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04752631. Inclusion in this directory is not an endorsement.